CN1350862A - Composition for treating leukoderma - Google Patents
Composition for treating leukoderma Download PDFInfo
- Publication number
- CN1350862A CN1350862A CN 00131115 CN00131115A CN1350862A CN 1350862 A CN1350862 A CN 1350862A CN 00131115 CN00131115 CN 00131115 CN 00131115 A CN00131115 A CN 00131115A CN 1350862 A CN1350862 A CN 1350862A
- Authority
- CN
- China
- Prior art keywords
- vitiligo
- treatment vitiligo
- commonly used
- compositions according
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A composition for treating leukoderma contains excipient, malaytea scurfpea extract or psovalen or mixture of psovalen and isopsovalen, filming agent, and percutaneous absorption promoter. Its advantages include high curative effect, high filming speed, no irritation and toxic reaction and low toxic by-effect.
Description
The present invention relates to a kind of treatment vitiligo compositions that contains Fructus Psoraleae (Fructus psoraleae), said composition is a dermatologic, is used for the treatment of the vitiligo disease.
Fructus Psoraleae uses as Chinese crude drug, has warming the kidney to activate YANG, improving inspiration by invigorating kidney-QI, diarrhea-relieving function, (referring to for example Pharmacopoeia of People's Republic of China, version in 2000, one one, 147 pages) as everyone knows.Fructus Psoraleae is also known as dermatologic treatment vitiligo, for example discloses a kind of tincture (referring to for example clinical department of dermatologry magazine, 1998,27 rolled up the 2nd phase, 98 pages) that contains Fructus Psoraleae.
Though the above-mentioned known tincture that contains Fructus Psoraleae is having suitable curative effect aspect the treatment vitiligo disease, but also exist the lasting poor permeability of Fructus Psoraleae, effective ingredient can not get sufficient utilization, thereby cause the curative effect reduction, and also exist the weak point of using inconvenience, easy mobile, easy pollution clothes.
The inventor of present patent application finds through further investigation, reasonable combination such as Fructus Psoraleae extract and filmogen and short cutaneous permeable agent are made liniment, with the Fructus Psoraleae tincture relatively: can make the effective ingredient of Fructus Psoraleae more see through skin and the lasting permeability of long period is arranged, thereby make curative effect be able to obvious raising; And the patient uses convenient, and the very fast medicine film that promptly forms after smearing does not flow, pollution clothes not; Have good safety, skin is not had acute toxic reaction and irritant reaction, reduced the toxic and side effects of Fructus Psoraleae tincture.
Purpose of the present invention is just in order to overcome above-mentioned weak point of the prior art, and provides a kind of new dosage form treatment vitiligo compositions of filming based on above-mentioned discovering.
Purpose of the present invention can realize by following measure:
Treatment vitiligo of the present invention comprises skin class pharmaceutical excipient commonly used with compositions, and with Fructus Psoraleae (Fructus psoraleae) extract as main active or unique active component, its active component can be the mixture of Fructus Psoraleae extract or psoralen or psoralen and isopsoralen, wherein also comprises filmogen and short cutaneous permeable agent.
Treatment vitiligo of the present invention specifically can be the medicine that is prepared by following weight percentages with compositions: skin class pharmaceutical excipient 30%～89% commonly used, Fructus Psoraleae extract are by medical material 10%～50%, filmogen 0.01%～15%, short cutaneous permeable agent 0.5%～6%.
Treatment vitiligo of the present invention specifically also can be the medicine that is prepared by following weight percentages with compositions: skin class pharmaceutical excipient 80%～99% commonly used, psoralen or psoralen and isopsoralen mixture 0.001%～1.0%, filmogen 0.01%～15%, short cutaneous permeable agent 0.5%～6%.
Filmogen described in the present invention is any one in polyvinyl alcohol, carbomer, polyvinylpyrrolidone, acrylic resin, cellulose and derivant thereof, medicine membrane resin, Rhizoma Bletillae gel, gelatin, zein, Pyroxylin, alginate, Pa Luoshamu, the agar; Described short cutaneous permeable agent is any one in laurocapram or the dimethyl sulfoxine.
Described skin class pharmaceutical excipient commonly used comprises substrate commonly used, wetting agent, surfactant, PH regulator and ethanol and distilled water; Substrate wherein commonly used is any one in vaseline, stearic acid, lanoline, the triethanolamine; Described wetting agent is any one in glycerol, mannitol, the sorbitol; Described surfactant is any one in the various models of polysorbate, sorbitan ester; Described PH regulator is any one in sodium hydroxide, hydrochloric acid, the acetic acid.Its consumption can enepidermic routinely amount ranges be determined.
The above-mentioned Fructus Psoraleae extract that contains is 20%～40% by the medical material preferred amounts, and the preferred amounts that contains psoralen or psoralen and isopsoralen mixture is 0.001%～0.2%.The typical material of described filmogen is a polyvinyl alcohol.The consumption of filmogen is decided on its kind and model, and for example the consumption of polyvinyl alcohol can be 1%～15%, and preferably 4%～8%.The consumption of carbomer can be 0.01%～5.0%, preferably 0.1%～2.0%.The preferred amounts of described short cutaneous permeable agent is 1%～4%.
Preparation method of the present invention is that the Fructus Psoraleae extract of appropriate amount, filmogen and short cutaneous permeable agent are dissolved in the alcohol-water solution, regulates pH value and can obtain product of the present invention.
Treatment vitiligo of the present invention can be used in the enepidermic pH value scope of routine with compositions, generally transfers pH value to 3.0～9.0, preferably to 5.0～7.5.
Treatment vitiligo of the present invention is with also adding antiseptic as required in right amount in the compositions, and described antiseptic can be any one in benzyl chloride alkanamine, Benzalkonium Bromide, chlorobutanol, p-Hydroxybenzoate, the hibitane.
Treatment vitiligo of the present invention can further comprise an amount of various Fructus Psoraleaes therapeutic component in addition with compositions, and prerequisite is that advantage of the present invention is not destroyed.
Treatment vitiligo of the present invention except that can making liniment or gel, also can be made into unguentum products such as (removal filmogens) with compositions.
Below experiment will further specify the present invention.
Test 1 stability experiment
Get this product three batch samples and carry out accelerated test, sample is placed in 40 ℃, the environment of relative humidity 75% 3 months, investigates the stability of product, sees Table 1.The result represents that this product has good stability, and with reference to new drug operating period Forecasting Methodology, the operating period of this product can be decided to be 2 years.
The influence of table 1 vitiligo liniment accelerated test lot number is because of shape PH ethanol % psoralen
Brown viscous liquid 6.8 43.4 991217 brown viscous liquids, 6.6 46.6 991218 brown viscous liquids, 7.0 45.6 991,216 1 months up to specification brown viscous liquid 6.7 42.2 991217 brown viscous liquids, 6.6 45.5 991218 brown viscous liquids, 7.1 44.8 991,216 3 months up to specification brown viscous liquid 6.6 41.7 991217 brown viscous liquids, 6.7 43.2 991218 brown viscous liquids 6.9 42.6 up to specification up to specification up to specification up to specification up to specification up to specification are up to specification before element 991216 tests
Test 2 skin acute toxicity testings
Observe animal intact skin and percutaneous of damaged skin are contacted the toxic reaction that is produced behind the vitiligo liniment.Divide 3 groups at random with 12 of rabbit, 4 every group, be respectively vehicle group, vitiligo liniment small dose group (clinical working concentration) and heavy dose of group (4 times of clinical working concentrations).24h is at back, rabbit right side depilation 150cm before the administration
2When checking depilation district skin zero damage, be coated with respectively and tried each 3ml of thing medicinal liquid, behind the effect 24h, throw off the medicine film and use warm water cleaning, observation is tried poisoning symptoms such as the behavior to the 7th day rabbit in 1,24,48,72 hour behind the thing, activity, fur gloss, diet and body weight continuously, if any dead animal, postmortem in time and perusal when pathological changes, are carried out histopathologic examination.
When test shows non-toxic reaction as intact skin, at the depilation 150cm of rabbit left dorsal portion
2, draw # shape scar with sterile needle behind the preserved skin, do not stab corium to stab epidermis, slight oozing of blood is advisable, coating immediately, observe the same, and with the vehicle group comparison.The acute toxicity test of table 2 vitiligo liniment skin (g, X ± SD, n=4) intact skin group damaged skin group excipient matched group body weight 1876 ± 58 1971 ± 62 2056 ± 57 before the administration of group project
Have a net increase of body weight 95 85
Poisoning symptom does not have no liniment small dose group body weight 1925 ± 74 2023 ± 77 2155 ± 82
Have a net increase of body weight 98 132
Poisoning symptom does not have the heavy dose of group of no liniment body weight 1892 ± 65 1981 ± 69 2062 ± 71
Have a net increase of body weight 89 81
Poisoning symptom does not have
Compare with matched group, be P＞0.05
Result of the test shows: behavior, activity, fur gloss, diet and the body weight of intact skin group and damaged skin group all animals are all acted normally, and not seeing has any poisoning symptom, observe in 14 days and do not have animal dead.The medicinal liquid of vitiligo liniment clinical dosage and its 4 times of clinical dosages is used in outward on the complete sum damaged skin of white rabbit, does not all cause acute toxic reaction.
Test 3 skin irritation tests
Observation animal intact skin and damaged skin repeatedly percutaneous contact the local excitation reaction that is produced behind the vitiligo liniment.Adopt consubstantiality left and right sides self matching type, 6 rabbit are divided into 2 groups at random, 3 every group, be respectively intact skin vitiligo liniment low dose of and heavy dose and vehicle group; Damaged skin vitiligo liniment low dose of and heavy dose and vehicle group.2 of the rabbit back spinal column both sides unhairing of being in, every 150cm
2The intact skin experimental animal is checked skin zero damage; The damaged skin experimental animal is drawn # shape scar with sterile needle after unhairing, epidermis is not stabbed corium, slightly oozing of blood is advisable to stab wound.The depilation district is coated with two kinds of each 1ml of vitiligo liniment respectively in the animal left side; Depilation district, right side is coated with excipient 1ml.Application area is 50cm
2, every interval is every keeping at a distance, and uses water proof paper and immobilization with adhesive tape respectively.The animal sub-cage rearing, every day coating once, throw off the medicine film behind the 24h, with warm water cleaning coating again, continuous 7 days, behind the last coating 24h, throw off the medicine film, observe and smear the position 1 week and have or not situations such as erythema and edema, write down score value and recovery situation and time in each in time, skin irritation intensity is estimated.Table 3 vitiligo liniment is to rabbit 1 day 3 days 7 days 1 day 3 days 7 days small dose group 0.33 0.00 0.00 1.33 0.33 0.00 heavy dose of group 1.00 0.00 0.00 1.67 0.67 0.33 vehicle group 0.67 0.00 0.00 1.67 0.33 0.00 of skin irritation reaction appraisal result test intact skin test damaged skin test period repeatedly
To intact skin and damaged skin repeatedly the irritant test result show that the vitiligo liniment is subjected to test solution and excipient contrast liquid that intact skin and damaged skin were all had slight stimulation in first day, intact skin recovered on the 3rd day, the heavy dose of group of damaged skin was recovered on the 7th day.The vitiligo liniment be subjected to test solution and excipient contrast liquid to intact skin and the 7th day average response value of damaged skin all less than 0.4, be nonirritant.
Test 4 pairs of leukodermic therapeutic tests
Be diagnosed as patients with vitiligo 86 examples, male's 49 examples wherein, women's 37 examples.19～62 years old age, 28 years old mean age.The course of disease 2 months～26 years, average 4.8 years.The main happening part of white macula is in head 35 examples, extremity 28 examples, trunk 23 examples.White macula maximum area 8 * 6cm
2, minimum area 0.5 * 1cm
2White macula is rounded, oval or irregular, clear-cut margin, hair is normal or bleach in the surface smoothing, speckle.Homeliness type 74 examples, wherein sporadic 41 examples, limitation 23 examples, general property 10 examples; Segmental pattern 12 examples, progressive stages 49 example, resting stages 37 example.Most humans (77 example) past was accepted different treatments, comprised external corticosteroid hormone, oral Chinese medicine etc., and effect is all not obvious.
The test case is through skin administration vitiligo liniment, and 1～2 time on the one, 6 months was 1 course of treatment, formulates standard by national pigment disease group, divides level Four to judge, and the statistics effective percentage.It is the shortest 8 days, the longest 24 months to observe medication, and most 1～6 month, average 5.5 months.Surpass 24 months and use additive method instead.The clinical efficacy of vitiligo liniment sees Table 4.The invalid effective percentage 86 26 (30.2%) 29 (33.7%) 18 (20.9%) 13 (15.1%) 84.9% of evaluation of clinical curative effect example number recovery from illness produce effects progress of table 4 vitiligo liniment
The vitiligo liniment has significant therapeutic effect to patients with vitiligo, can obviously change the pigment at skin lesion position, makes skin color recover normal.Most of experimenters used 6 months continuously, and untoward reaction is not observed in the longest use 24 months.The result shows that the vitiligo liniment has good tolerability.
The invention has the advantages that the effective ingredient that not only can make Fructus Psoraleae can be more sees through skin and the lasting permeability of long period is arranged, thereby make curative effect be able to obvious raising; And the patient uses convenient, and the very fast medicine film that promptly forms after smearing does not flow, pollution clothes not; Have good safety, skin is not had acute toxic reaction and irritant reaction, reduced the toxic and side effects of Fructus Psoraleae tincture.
The present invention does with detailed description below with reference to embodiment, but it should be considered as limitation of the present invention.
Embodiment 1
Press the compositions of a kind of liniment form of prescription preparation:
The composition consumption
Fructus Psoraleae extract 25.0ml
Polyvinyl alcohol 5.0g
Laurocapram 3.0ml
Glycerol 10.0ml
Polysorbate 10.0ml
Ethanol 45.0ml
Distilled water adds to 100ml
Fructus Psoraleae extract, laurocapram, glycerol, Polysorbate are dissolved in respectively in the polyvinyl alcohol that was soaked in water, add ethanol, add water to full dose, stir, transfer PH, promptly.
Embodiment 2
Press the compositions of a kind of gel form of prescription preparation:
The composition consumption
Psoralen 0.2mg
Carbomer 0.5g
Laurocapram 3.0ml
Glycerol 10.0ml
Polysorbate 5.0ml
Ethanol 50.0ml
Distilled water adds to 100ml
Psoralen, laurocapram, glycerol, Polysorbate are dissolved in respectively in the carbomer that was soaked in water, add ethanol, add water to full dose, stir, transfer PH, promptly.
Claims (10)
1, a kind of treatment vitiligo compositions, it comprises skin class pharmaceutical excipient commonly used, and Fructus Psoraleae (Fructus psoraleae) extract or psoralen or psoralen and isopsoralen mixture, it is characterized in that: also contain filmogen and short cutaneous permeable agent in the said composition.
2, treatment vitiligo compositions according to claim 1 is characterized in that: it is the medicine by the following weight percentages preparation: skin class pharmaceutical excipient 30%～89% commonly used, Fructus Psoraleae extract are by medical material 10%～50%, filmogen 0.01%～15%, short cutaneous permeable agent 0.5%～6%.
3, treatment vitiligo compositions according to claim 1 is characterized in that: it is the medicine by the following weight percentages preparation: skin class pharmaceutical excipient 80%～99% commonly used, psoralen or psoralen and isopsoralen mixture 0.001%～1.0%, filmogen 0.01%～15%, short cutaneous permeable agent 0.5%～6%.
4, according to claim 1 or 2 or 3 described treatment vitiligo compositionss, it is characterized in that: described filmogen is any one in polyvinyl alcohol, carbomer, polyvinylpyrrolidone, acrylic resin, cellulose and derivant thereof, medicine membrane resin, Rhizoma Bletillae gel, gelatin, zein, Pyroxylin, alginate, Pa Luoshamu, the agar.
5, according to claim 1 or 2 or 3 described treatment vitiligo compositionss, it is characterized in that: described short cutaneous permeable agent is any one in laurocapram or the dimethyl sulfoxine.
6, according to claim 1 or 2 or 3 described treatment vitiligo compositionss, it is characterized in that: described skin class pharmaceutical excipient commonly used comprises substrate commonly used, wetting agent, surfactant, PH regulator and ethanol and distilled water.
7, treatment vitiligo compositions according to claim 6 is characterized in that: described substrate commonly used is any one in vaseline, stearic acid, lanoline, the triethanolamine.
8, treatment vitiligo compositions according to claim 6, it is characterized in that: described wetting agent is any one in glycerol, mannitol, the sorbitol.
9, treatment vitiligo compositions according to claim 6 is characterized in that: described surfactant is any one in the various models of polysorbate, sorbitan ester.
10, treatment vitiligo compositions according to claim 6 is characterized in that: described PH regulator is any one in sodium hydroxide, hydrochloric acid, the acetic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001311158A CN1327836C (en) | 2000-11-01 | 2000-11-01 | Composition for treating leukoderma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001311158A CN1327836C (en) | 2000-11-01 | 2000-11-01 | Composition for treating leukoderma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1350862A true CN1350862A (en) | 2002-05-29 |
| CN1327836C CN1327836C (en) | 2007-07-25 |
Family
ID=4594475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001311158A Expired - Fee Related CN1327836C (en) | 2000-11-01 | 2000-11-01 | Composition for treating leukoderma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1327836C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408034C (en) * | 2006-01-24 | 2008-08-06 | 河南辅仁药业集团有限公司 | Traditional Chinese medicine preparation for treating leukoderma, psoriasis and its preparation method |
| CN104368035A (en) * | 2013-08-13 | 2015-02-25 | 凌峰 | Biological dressing for eliminating white spots and scars on human body |
| CN105726401A (en) * | 2016-03-21 | 2016-07-06 | 天水师范学院 | Cosmetic formulation with curative effect on small-area leucoderma and preparation method of cosmetic formulation |
| CN107233313A (en) * | 2017-04-26 | 2017-10-10 | 哈尔滨医科大学 | Psoralen nano cubic liquid crystal preparation capable of permeating skin and its preparation method and application |
| CN110339257A (en) * | 2019-08-20 | 2019-10-18 | 江苏博润医疗集团有限公司 | It is a kind of for treating the external drug of leucoderma |
| CN111747965A (en) * | 2020-07-07 | 2020-10-09 | 南京宸翔医药研究有限责任公司 | Method for digitally, greenly and intelligently preparing high-purity fructus psoraleae component groups or monomers and pharmaceutical composition thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1120722C (en) * | 1999-02-25 | 2003-09-10 | 吴克 | Externalty used paste for treating leukoderma, leukoplakia valvae and other vitiligines, and its preparing method |
-
2000
- 2000-11-01 CN CNB001311158A patent/CN1327836C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408034C (en) * | 2006-01-24 | 2008-08-06 | 河南辅仁药业集团有限公司 | Traditional Chinese medicine preparation for treating leukoderma, psoriasis and its preparation method |
| CN104368035A (en) * | 2013-08-13 | 2015-02-25 | 凌峰 | Biological dressing for eliminating white spots and scars on human body |
| CN105726401A (en) * | 2016-03-21 | 2016-07-06 | 天水师范学院 | Cosmetic formulation with curative effect on small-area leucoderma and preparation method of cosmetic formulation |
| CN107233313A (en) * | 2017-04-26 | 2017-10-10 | 哈尔滨医科大学 | Psoralen nano cubic liquid crystal preparation capable of permeating skin and its preparation method and application |
| CN107233313B (en) * | 2017-04-26 | 2020-04-10 | 哈尔滨医科大学 | Psoralen nano cubic liquid crystal transdermal preparation and preparation method and application thereof |
| CN110339257A (en) * | 2019-08-20 | 2019-10-18 | 江苏博润医疗集团有限公司 | It is a kind of for treating the external drug of leucoderma |
| CN111747965A (en) * | 2020-07-07 | 2020-10-09 | 南京宸翔医药研究有限责任公司 | Method for digitally, greenly and intelligently preparing high-purity fructus psoraleae component groups or monomers and pharmaceutical composition thereof |
| CN111747965B (en) * | 2020-07-07 | 2022-04-19 | 南京宸翔医药研究有限责任公司 | Method for digitally, greenly and intelligently preparing high-purity fructus psoraleae component groups or monomers and pharmaceutical composition thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1327836C (en) | 2007-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4296104A (en) | Therapeutic dimethyl sulfoxide composition and methods of use | |
| JP2953625B2 (en) | Method for reducing skin irritation associated with drug / penetration enhancing compositions | |
| EP0104037B1 (en) | Antiinflammatory and analgesic gel | |
| CN104922130B (en) | It is a kind of to be used to treat gelling agent of herpes zoster and preparation method thereof | |
| CN104306358B (en) | Antipruritic scar liniment of dispelling | |
| DE112013001457T5 (en) | Transdermal application system | |
| JP7320559B2 (en) | Compositions and methods of treatment | |
| TWI503133B (en) | A treatment composition | |
| CN1350862A (en) | Composition for treating leukoderma | |
| US8367683B2 (en) | Composition and method for treatment of warts | |
| CN110693860A (en) | Gel plaster containing ketoprofen and preparation method thereof | |
| CN112521389B (en) | Medicament and method for promoting wound healing | |
| RU2611400C2 (en) | Wound healing gel for external application | |
| CN1806850A (en) | Transdermal drug delivery intensifier composition and its application in externally applied medicine | |
| CN101703667A (en) | Brown red medicament for treating traumatic injuries and preparation method thereof | |
| CN1251753C (en) | Externally-applied medicine composition for treating mastoproliferation and its prepn | |
| CN1539410A (en) | Externally applied combined remedy for treating breast disease and preparation method | |
| CN114469969B (en) | Application of pulsatilla saponin B5 in preparation of skin care products | |
| CN114452292B (en) | Application of pulsatilla saponin B4 in preparation of skin care products | |
| CN1056774C (en) | Keyoulin sterilizing bactericide | |
| CN1393221A (en) | Liquid medicine for treating acne | |
| CN100540028C (en) | Liniment of treatment traumatic injury, rheumatic ostalgia and preparation method thereof | |
| CN1172680C (en) | Locally applied composite medicine for treating pointed condyloma | |
| CN101138543A (en) | Centella asiatica partial film forming gel composition and uses thereof | |
| CN1452982A (en) | Mucosa administrated Ribavirin prepn for preventing & curing SARS and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070725 Termination date: 20091201 |